| | ||||
 |
|
|||
 >4x |
Module 209 -- Catabolic peptidases |
| General Properties | |
|---|---|
| Below we list the number of gene sets from which the module was composed was originally composed, and the number of genes and experiments that it contains. Clicking on the number of genes will display a detailed list of all the genes in the module. Clicking on the number of experiments will display a detailed list of all the experiments in the module. | |
| Num gene sets: | 5 |
| Num genes: | 89 (see 1425 additional genes for this module) |
| Num experiments: | 702 (286 induced, 416 repressed) |
| Parent module: | None |
| Children modules: | 172 |
| Gene sets | |
|---|---|
| Below we list the gene sets from which the module was originally composed. Clicking on a gene set will display all the genes associated with that gene set. Also listed are all the other modules in which the gene set participates. | |
| endopeptidase activity | |
| catabolism | |
| regulation of catabolism | |
| proteolysis and peptidolysis | |
| peptidase activity | |
| Enriched clinical annotations | |||||||
|---|---|---|---|---|---|---|---|
| For each of the clinical annotations, we tested whether it was enriched in the set of arrays in which the module is significantly induced (or repressed). Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of induced (or repressed) module's arrays in which they appear. We also show the fraction of the module's induced (or repressed) arrays with the given annotation ('Hits (%)' column). For completeness, we also list the total number of relevant induced arrays in the module ('Module hits in category' column), total number of arrays in the compendium in which the corresponding annotation is present ('Arrays in annotation' column), and the total number of relevant arrays in the compendium ('Arrays' column). Note that the 'relevant' arrays may be different for each annotation, since it includes only arrays in which the annotation was relevant (i.e., present or not present) and excludes arrays where the value of the annotation was not known. Rows that correspond to annotations that were enriched in the induced arrays of the module have a red background, while rows corresponding to annotations enriched in the repressed arrays have a green background. For each annotation, we also list the other modules in which it was enriched. | |||||||
| Clinical annotation | Category | P-value | Hits | Hits(%) | Module hits in category | Arrays in annotation | Arrays |
| Liver tissue (Liver cancer*) | Liver cancer* | 9.7e-38 | 97 | 33.9 | 286 | 187 | 1945 |
| Liver tissue, cancer or cell line (Liver cancer*) | Liver cancer* | 3.5e-35 | 97 | 33.9 | 286 | 197 | 1945 |
| Cancer and cell line (Lung cancer*) | Lung cancer* | 2.9e-29 | 128 | 30.8 | 415 | 252 | 1945 |
| Cancer (Lung cancer*) | Lung cancer* | 2.9e-29 | 128 | 30.8 | 415 | 252 | 1945 |
| Lung tissue, cancer or cell line (Lung cancer*) | Lung cancer* | 1.7e-27 | 133 | 32.0 | 415 | 276 | 1945 |
| Lung cancer (Lung cancer*) | Lung cancer* | 1.7e-25 | 118 | 28.4 | 415 | 238 | 1945 |
| Lung cancer or cell line (Lung cancer*) | Lung cancer* | 1.7e-25 | 118 | 28.4 | 415 | 238 | 1945 |
| Hepatitis infected liver (Liver cancer*) | Liver cancer* | 7.1e-25 | 74 | 25.8 | 286 | 156 | 1945 |
| Non-tumor liver tissue (Liver cancer) | Liver cancer | 6.6e-21 | 67 | 69.0 | 97 | 76 | 207 |
| Cancer and cell line (Liver cancer) | Liver cancer | 1.0e-15 | 61 | 98.3 | 62 | 126 | 207 |
| Non small cell lung cancer and cell line (Lung cancer*) | Lung cancer* | 9.5e-15 | 90 | 21.6 | 415 | 205 | 1945 |
| Non small cell lung cancer (Lung cancer*) | Lung cancer* | 9.5e-15 | 90 | 21.6 | 415 | 205 | 1945 |
| Diffuse large B cell lymphoma - DLBCL (B lymphoma) | B lymphoma | 3.6e-13 | 45 | 95.7 | 47 | 126 | 245 |
| Diffuse large B cell lymphoma tumor or cell line (B lymphoma) | B lymphoma | 9.4e-12 | 45 | 95.7 | 47 | 134 | 245 |
| Chronic lymphocytic leukemia (B lymphoma) | B lymphoma | 3.3e-10 | 31 | 45.5 | 68 | 46 | 245 |
| Leukemia (B lymphoma) | B lymphoma | 3.3e-10 | 31 | 45.5 | 68 | 46 | 245 |
| Leukemia or leukemia cell line (B lymphoma) | B lymphoma | 3.3e-10 | 31 | 45.5 | 68 | 46 | 245 |
| B cells (Leukemia) | Leukemia | 2.1e-09 | 24 | 96 | 25 | 62 | 141 |
| Cell line (Breast cancer) | Breast cancer | 6.1e-09 | 20 | 57.1 | 35 | 30 | 152 |
| CNS tissue, cancer or cell line (Various tumors) | Various tumors | 9.3e-09 | 15 | 51.7 | 29 | 21 | 154 |
| Activated B like DLBCL (B lymphoma) | B lymphoma | 9.3e-09 | 19 | 40.4 | 47 | 30 | 245 |
| Bone marrow (Leukemia) | Leukemia | 1.3e-08 | 15 | 60 | 25 | 23 | 141 |
| Breast cancer cell line (Breast cancer) | Breast cancer | 4.5e-08 | 14 | 40 | 35 | 17 | 152 |
| Cancer (Liver cancer) | Liver cancer | 2.0e-07 | 51 | 82.2 | 62 | 115 | 207 |
| CNS cancer or cell line (Various tumors) | Various tumors | 2.4e-07 | 12 | 41.3 | 29 | 16 | 154 |
| CNS tumor (Various tumors) | Various tumors | 2.4e-07 | 12 | 41.3 | 29 | 16 | 154 |
| Lymphoma or lymphoma cell line (B lymphoma) | B lymphoma | 6.0e-07 | 45 | 95.7 | 47 | 167 | 245 |
| Female hormonal cancer cell line (Breast cancer) | Breast cancer | 1.1e-06 | 12 | 34.2 | 35 | 15 | 152 |
| Liver cancer cell line (Liver cancer) | Liver cancer | 3.3e-06 | 10 | 16.1 | 62 | 10 | 207 |
| Metastasis (Liver cancer) | Liver cancer | 3.3e-06 | 10 | 16.1 | 62 | 10 | 207 |
| Normal tissue (Liver cancer) | Liver cancer | 1.4e-05 | 14 | 14.4 | 97 | 14 | 207 |
| Acute lymphocytic leukemia (Leukemia) | Leukemia | 1.7e-05 | 29 | 96.6 | 30 | 99 | 149 |
| Cell line (Liver cancer) | Liver cancer | 2.8e-05 | 10 | 16.1 | 62 | 11 | 207 |
| GC B like DLBCL (B lymphoma) | B lymphoma | 5.9e-05 | 21 | 44.6 | 47 | 53 | 245 |
| Invasive liver tumor (Liver cancer) | Liver cancer | 6.4e-05 | 22 | 35.4 | 62 | 38 | 207 |
| Lung carcinoid (Lung cancer) | Lung cancer | 6.5e-05 | 18 | 13.5 | 133 | 20 | 276 |
| Adenocarcinoma (Liver cancer) | Liver cancer | 7.1e-05 | 42 | 67.7 | 62 | 97 | 207 |
| Lymphocytes (Leukemia) | Leukemia | 8.7e-05 | 24 | 96 | 25 | 91 | 141 |
| Malignant glioblastoma (Various tumors) | Various tumors | 0.0001 | 7 | 24.1 | 29 | 9 | 154 |
| Centroblasts (Various tumors) | Various tumors | 0.0001 | 5 | 17.2 | 29 | 5 | 154 |
| GC B like DLBCL (Various tumors) | Various tumors | 0.0001 | 5 | 17.2 | 29 | 5 | 154 |
| Adenocarcinoma (Breast cancer*) | Breast cancer* | 0.0001 | 31 | 10.8 | 286 | 112 | 1945 |
| Breast cancer (Breast cancer*) | Breast cancer* | 0.0001 | 31 | 10.8 | 286 | 112 | 1945 |
| Cancer (Breast cancer*) | Breast cancer* | 0.0001 | 31 | 10.8 | 286 | 112 | 1945 |
| Female hormonal cancer (Breast cancer*) | Breast cancer* | 0.0001 | 31 | 10.8 | 286 | 112 | 1945 |
| Enriched GO annotations | ||||||
|---|---|---|---|---|---|---|
| For each GO annotation, we tested whether it was enriched in the set of genes of the module. Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of the module's genes in which they appear. We also show the fraction of the module's genes with the given GO annotation that are included in this module ('Hits (%)' column). For completeness, we also list the total number of genes in the module ('Module genes' column), total number of genes in the compendium in which the corresponding annotation is present ('Genes in annotation' column), and the total number of genes in the compendium ('Genes' column). | ||||||
| GO annotation | P-value | Hits | Hits(%) | Module genes | Genes in annotation | Genes |
| catabolism | 1.6e-97 | 78 | 87.6 | 89 | 215 | 4566 |
| proteolysis and peptidolysis | 2.0e-85 | 69 | 77.5 | 89 | 176 | 4566 |
| peptidase activity | 6.6e-78 | 67 | 75.2 | 89 | 193 | 4566 |
| regulation of catabolism | 6.5e-72 | 61 | 68.5 | 89 | 162 | 4566 |
| regulation of metabolism | 2.8e-55 | 66 | 74.1 | 89 | 365 | 4566 |
| endopeptidase activity | 5.8e-46 | 40 | 44.9 | 89 | 99 | 4566 |
| hydrolase activity | 1.2e-44 | 75 | 84.2 | 89 | 783 | 4566 |
| serine-type endopeptidase activity | 6.8e-37 | 31 | 34.8 | 89 | 69 | 4566 |
| serine-type peptidase activity | 4.3e-36 | 32 | 35.9 | 89 | 80 | 4566 |
| chymotrypsin activity | 1.2e-33 | 26 | 29.2 | 89 | 48 | 4566 |
| trypsin activity | 5.5e-33 | 26 | 29.2 | 89 | 50 | 4566 |
| catalytic activity | 9.1e-30 | 83 | 93.2 | 89 | 1677 | 4566 |
| metallopeptidase activity | 1.8e-20 | 21 | 23.5 | 89 | 70 | 4566 |
| metalloexopeptidase activity | 2.4e-14 | 11 | 12.3 | 89 | 21 | 4566 |
| carboxylic acid catabolism | 2.4e-14 | 13 | 14.6 | 89 | 35 | 4566 |
| exopeptidase activity | 1.4e-12 | 10 | 11.2 | 89 | 21 | 4566 |
| cysteine-type peptidase activity | 2.1e-10 | 10 | 11.2 | 89 | 32 | 4566 |
| collagen catabolism | 1.3e-09 | 7 | 7.8 | 89 | 13 | 4566 |
| zinc ion binding | 1.3e-09 | 15 | 16.8 | 89 | 108 | 4566 |
| protein catabolism | 5.8e-09 | 8 | 8.9 | 89 | 23 | 4566 |
| metal ion binding | 6.0e-09 | 27 | 30.3 | 89 | 410 | 4566 |
| cysteine-type endopeptidase activity | 8.6e-09 | 8 | 8.9 | 89 | 24 | 4566 |
| metalloendopeptidase activity | 1.0e-08 | 10 | 11.2 | 89 | 46 | 4566 |
| macromolecule catabolism | 1.2e-08 | 8 | 8.9 | 89 | 25 | 4566 |
| metallocarboxypeptidase activity | 1.9e-08 | 6 | 6.7 | 89 | 11 | 4566 |
| transition metal ion binding | 4.7e-08 | 16 | 17.9 | 89 | 160 | 4566 |
| lipid catabolism | 6.2e-08 | 8 | 8.9 | 89 | 30 | 4566 |
| carboxypeptidase activity | 7.1e-08 | 6 | 6.7 | 89 | 13 | 4566 |
| sterol regulatory element-binding protease activity | 7.8e-08 | 7 | 7.8 | 89 | 21 | 4566 |
| blood coagulation | 2.4e-07 | 9 | 10.1 | 89 | 48 | 4566 |
| carboxylic acid metabolism | 3.0e-07 | 14 | 15.7 | 89 | 138 | 4566 |
| organic acid metabolism | 3.2e-07 | 14 | 15.7 | 89 | 139 | 4566 |
| hemostasis | 3.5e-07 | 9 | 10.1 | 89 | 50 | 4566 |
| blood coagulation factor activity | 5.8e-07 | 5 | 5.6 | 89 | 10 | 4566 |
| carboxypeptidase A activity | 5.8e-07 | 5 | 5.6 | 89 | 10 | 4566 |
| extracellular space | 2.2e-06 | 16 | 17.9 | 89 | 212 | 4566 |
| defense/immunity protein activity | 3.7e-06 | 11 | 12.3 | 89 | 103 | 4566 |
| lipase activity | 4.3e-06 | 5 | 5.6 | 89 | 14 | 4566 |
| carboxylic ester hydrolase activity | 7.7e-06 | 6 | 6.7 | 89 | 26 | 4566 |
| complement activity | 1.7e-05 | 5 | 5.6 | 89 | 18 | 4566 |
| aspartic-type endopeptidase activity | 6.9e-05 | 3 | 3.3 | 89 | 5 | 4566 |
| regulation of complement activation | 9.8e-05 | 5 | 5.6 | 89 | 25 | 4566 |
| lysosome | 0.0001 | 7 | 7.8 | 89 | 57 | 4566 |
| complement activation | 0.0001 | 5 | 5.6 | 89 | 26 | 4566 |
| Visual display | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Below is a visual display of the module. Shown are those arrays in which the module's genes significantly change, and the direction of change (induction/repression) in each array is indicated (middle, labeled 'Module changes'; red/green row). The arrays that correspond to the significant clinical attributes are also shown (top; brown rows). The gene sets that compose the module are also shown (left) along with an indication of the membership of the module genes in these gene sets. | |||||||||
| You can also view the images within GeneXPress by loading the module gxp file file. | |||||||||
| Note: Since there are 702 experiments, this image does not display the individual experiment names, but rather condenses each experiment to a single pixel without displaying its name. You can fully view the image for this module within GeneXPress, by loading any of the four files mentioned in the line above | |||||||||
|
|||||||||
